Besides iCCA, FGF1 sustains the survival of dormant cancer cells in breast cancer, modulates senescence-associated malignancy in prostate cancer, and reactivates RAF-MEK signaling in pancreatic ductal adenocarcinoma to bypass targeted inhibition [48–50]. Here, PRRT2 is linked to prostate cancer.